U.S. Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report By Test, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Test
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Objectives
  • 1.3.1. Objective-1
  • 1.3.2. Objective-2
  • 1.3.3. Objective-3
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased database
  • 1.5.2. GVR's internal database
  • 1.5.3. Secondary sources
  • 1.5.4. Primary research
• 1.6. Information or Data Analysis
  • 1.6.1. Data analysis models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity flow analysis
    • 1.8.1.1. Approach 1: Commodity flow approach
    • 1.8.1.2. Approach 2: Country-wise market estimation using bottom-up approach
• 1.9. List of Secondary Sources
• 1.10. List of Primary Sources
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Test Snapshot
• 2.3. Application and End-use Snapshot
• 2.4. Competitive Insights

Chapter 3. U.S. Latent Tuberculosis Infection Detection Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook (Latent Tuberculosis Infection Detection Market)
  • 3.1.2. Related/ancillary market outlook (Tuberculosis Diagnostics Market)
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increase in risk of developing active Tuberculosis Infection from LTBI
    • 3.2.1.2. Increasing Funding Programs to Promote TB Diagnostics
    • 3.2.1.3. Technological Advancements in Diagnostics Methods
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Limited Awareness and Underdiagnosis of Latent TB
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Growing Focus on TB Elimination and Preventive Care
    • 3.2.3.2. Expansion of Community-Based and Targeted Screening Programs
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Low Disease Visibility and Competing Public Health Priorities
• 3.3. U.S. Latent Tuberculosis Infection Detection Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
• 3.4. Regulatory Framework
• 3.5. Reimbursement Scenario
• 3.6. Payment/ Reimbursement for Immigration Testing
• 3.7. CLIA Labs in the U.S.
  • 3.7.1. List of all the CLIA Labs in the U.S
  • 3.7.2. List of CLIA and NYS Certified Labs that Perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their Volumes
  • 3.7.3. List of Physicians and Volumes Ordered of the Tests Split out by NPI, Geography, and Practice

Chapter 4. U.S. Latent Tuberculosis Infection Detection Market: Test Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Latent Tuberculosis Infection Detection Market: Test Movement Analysis
• 4.3. U.S. Latent Tuberculosis Infection Detection Market by Test Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 4.5. Interferon Gamma Released Assay (IGRA)
  • 4.5.1. Interferon Gamma Released Assay (IGRA) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Interferon Gamma Released Assay (IGRA) Market Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 4.5.3. QFT
    • 4.5.3.1. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3.2. QFT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
  • 4.5.4. T. SPOT
    • 4.5.4.1. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4.2. T. SPOT Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 4.6. Tuberculin Skin Test (TST)
  • 4.6.1. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Tuberculin Skin Test (TST) Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 5. U.S. Latent Tuberculosis Infection Detection Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Latent Tuberculosis Infection Detection Market: Application Movement Analysis
• 5.3. U.S. Latent Tuberculosis Infection Detection Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 5.5. Household Contacts With Pulmonary TB
  • 5.5.1. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Household Contacts With Pulmonary TB Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 5.6. PLHIV
  • 5.6.1. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.2. PLHIV Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.2. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 6. U.S. Latent Tuberculosis Infection Detection Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Latent Tuberculosis Infection Detection Market: End Use Movement Analysis
• 6.3. U.S. Latent Tuberculosis Infection Detection Market by End Use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033, for the following
• 6.5. Diagnostic Laboratories
  • 6.5.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 6.6. Hospitals/Clinics
  • 6.6.1. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Hospitals/Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)
• 6.7. Academic & Research Institutions
  • 6.7.1. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Academic & Research Institutions Market Revenue Estimates and Forecasts, 2021 - 2033 (Number of Tests, in Thousands)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2025
• 7.4. Key Company Profiles
  • 7.4.1. QIAGEN
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Euroimmun US
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. bioMerieux
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Oxford Immunotec
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. SD Biosensor, INC.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Quest Diagnostics
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. LabCorp
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. ARUP Laboratories
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Mayo Clinic Laboratories
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. BioReference Laboratories
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Par Pharmaceutical, Inc.
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 List of all the CLIA labs in the U.S
• Table 4 List of CLIA and NYS certified labs that perform QFT (CPT 86480), T-SPOT.TB (86481), TST (86580), and their volumes
• Table 5 List of physicians and volumes ordered of the tests, split out by NPI, geography, and practice
• Table 6 U.S. latent tuberculosis infection detection market, by test, 2021 - 2033 (USD Million)
• Table 7 U.S. latent tuberculosis infection detection market, by application, 2021 - 2033 (USD Million)
• Table 8 U.S. latent tuberculosis infection detection market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 U.S. latent tuberculosis infection detection market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. latent tuberculosis infection detection market snapshot
• Fig. 10 Test snapshot
• Fig. 11 Application and end-use snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Parent market outlook
• Fig. 14 Related/ancillary market outlook
• Fig. 15 Market dynamics
• Fig. 16 Market driver analysis (current & future impact)
• Fig. 17 Market restraint analysis (current & future impact)
• Fig. 18 Porter's five forces analysis
• Fig. 19 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 20 U.S. latent tuberculosis infection detection market, test outlook key takeaways
• Fig. 21 U.S. latent tuberculosis infection detection market, test movement analysis
• Fig. 22 IGRA market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 23 IGRA market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 24 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 25 Tuberculin Skin Test (TST) market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 26 QFT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 27 QFT market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 28 T.SPOT market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 29 T.SPOT market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 30 U.S. latent tuberculosis infection detection market, application outlook key takeaways
• Fig. 31 U.S. latent tuberculosis infection detection market, application movement analysis
• Fig. 32 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 33 Household Contacts with Pulmonary TB market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 34 PLHIV market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 35 PLHIV market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 36 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 37 Others market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 38 U.S. latent tuberculosis infection detection market, end use outlook key takeaways
• Fig. 39 U.S. latent tuberculosis infection detection market, end use movement analysis
• Fig. 40 Diagnostic Laboratories market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 41 Diagnostic Laboratories market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 42 Hospitals/Clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 43 Hospitals/Clinics market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 44 Academic & Research Institutions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 45 Academic & Research Institutions market revenue estimates and forecasts, 2021 - 2033 (Number of Tests in Thousands)
• Fig. 46 Key company categorization
• Fig. 47 Strategy mapping